Precision BioSciences, Inc. (DTIL) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
DTIL Revenue Growth
Revenue Breakdown (FY 2025)
DTIL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
DTIL Revenue Analysis (2016–2025)
As of May 8, 2026, Precision BioSciences, Inc. (DTIL) generated trailing twelve-month (TTM) revenue of $45.1 million, reflecting explosive growth of +37272.4% year-over-year. The most recent quarter (Q1 2026) recorded $10.8 million in revenue, down 68.3% sequentially.
Looking at the longer-term picture, DTIL's 5-year compound annual growth rate (CAGR) stands at +7.1%, indicating steady revenue expansion. The company achieved its highest annual revenue of $115.5 million in 2021.
Revenue diversification analysis shows DTIL's business is primarily driven by License (100%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BEAM (+108.0% YoY), CRSP (-88.9% YoY), and NTLA (+16.9% YoY), DTIL has outperformed the peer group in terms of revenue growth. Compare DTIL vs BEAM →
DTIL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DTILCurrent | $45M | +37272.4% | +7.1% | -152.2% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% |
DTIL Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $34.3M | -50.1% | $31.5M | 92.0% | $-52,148,000 | -152.2% |
| 2024 | $68.7M | +41.0% | $68.7M | 100.0% | $-26,162,000 | -38.1% |
| 2023 | $48.7M | +94.1% | $48.7M | 100.0% | $-43,736,000 | -89.8% |
| 2022 | $25.1M | -78.3% | $25.1M | 100.0% | $-62,308,000 | -248.3% |
| 2021 | $115.5M | +375.7% | $115.5M | 100.0% | $-39,376,000 | -34.1% |
| 2020 | $24.3M | +9.2% | $24.3M | 100.0% | $-109,828,000 | -452.2% |
| 2019 | $22.2M | +104.3% | $22.2M | 100.0% | $-87,204,000 | -392.1% |
| 2018 | $10.9M | +67.8% | $10.9M | 100.0% | $-47,912,000 | -440.2% |
| 2017 | $6.5M | -7.6% | $6.5M | 100.0% | $-21,974,000 | -338.9% |
| 2016 | $7.0M | - | $7.0M | 100.0% | $-8,828,000 | -125.8% |
See DTIL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DTIL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DTIL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDTIL — Frequently Asked Questions
Quick answers to the most common questions about buying DTIL stock.
Is DTIL's revenue growth accelerating or slowing?
DTIL revenue is accelerating at +37272.4% year-over-year, exceeding the 5-year CAGR of +7.1%. TTM revenue reached $45M. Growth momentum has increased versus prior periods.
What is DTIL's long-term revenue growth rate?
Precision BioSciences, Inc.'s 5-year revenue CAGR of +7.1% reflects the sustained expansion pattern. Current YoY growth of +37272.4% is above this long-term average.
How is DTIL's revenue distributed by segment?
DTIL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.